 Jody Tanabe
Concepts (324)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 62 | 2026 | 3863 | 3.650 |
Why?
| | Substance-Related Disorders | 18 | 2019 | 1094 | 3.020 |
Why?
| | Brain | 38 | 2025 | 2933 | 2.470 |
Why?
| | Brain Mapping | 23 | 2024 | 536 | 2.040 |
Why?
| | Nerve Net | 8 | 2019 | 285 | 1.570 |
Why?
| | Cerebrovascular Circulation | 8 | 2022 | 280 | 1.530 |
Why?
| | Cerebral Cortex | 15 | 2019 | 464 | 1.530 |
Why?
| | Prefrontal Cortex | 6 | 2017 | 328 | 1.320 |
Why?
| | Image Processing, Computer-Assisted | 22 | 2019 | 780 | 1.260 |
Why?
| | Acetates | 2 | 2021 | 80 | 1.250 |
Why?
| | Decision Making | 9 | 2017 | 975 | 1.240 |
Why?
| | Impulsive Behavior | 7 | 2015 | 146 | 1.160 |
Why?
| | High-Intensity Focused Ultrasound Ablation | 2 | 2026 | 13 | 1.160 |
Why?
| | Neuroimaging | 7 | 2025 | 289 | 1.110 |
Why?
| | Frontal Lobe | 7 | 2015 | 160 | 1.100 |
Why?
| | Gambling | 5 | 2015 | 30 | 0.990 |
Why?
| | Essential Tremor | 2 | 2026 | 24 | 0.980 |
Why?
| | Thalamus | 4 | 2021 | 125 | 0.900 |
Why?
| | Nicotine | 6 | 2013 | 331 | 0.880 |
Why?
| | Limbic System | 4 | 2015 | 55 | 0.860 |
Why?
| | Skull | 1 | 2026 | 158 | 0.860 |
Why?
| | Frontotemporal Dementia | 1 | 2024 | 57 | 0.820 |
Why?
| | Alzheimer Disease | 5 | 2025 | 621 | 0.810 |
Why?
| | Behavior | 3 | 2021 | 91 | 0.800 |
Why?
| | Risk-Taking | 3 | 2015 | 328 | 0.800 |
Why?
| | Psychotic Disorders | 2 | 2024 | 186 | 0.750 |
Why?
| | Nicotinic Agonists | 5 | 2011 | 136 | 0.720 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2019 | 186 | 0.720 |
Why?
| | Learning | 2 | 2019 | 452 | 0.690 |
Why?
| | Functional Neuroimaging | 2 | 2019 | 60 | 0.690 |
Why?
| | Sex Characteristics | 4 | 2020 | 790 | 0.660 |
Why?
| | Neostriatum | 2 | 2014 | 37 | 0.660 |
Why?
| | Pursuit, Smooth | 4 | 2005 | 19 | 0.660 |
Why?
| | Neuropsychiatry | 1 | 2020 | 17 | 0.660 |
Why?
| | Reward | 3 | 2023 | 247 | 0.650 |
Why?
| | Psychomotor Performance | 5 | 2017 | 328 | 0.630 |
Why?
| | Neural Pathways | 6 | 2017 | 311 | 0.630 |
Why?
| | Parkinson Disease | 4 | 2026 | 600 | 0.610 |
Why?
| | Alcoholism | 4 | 2021 | 817 | 0.600 |
Why?
| | Software | 1 | 2024 | 690 | 0.590 |
Why?
| | Craving | 1 | 2019 | 39 | 0.580 |
Why?
| | Central Nervous System Depressants | 1 | 2019 | 83 | 0.580 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2019 | 64 | 0.580 |
Why?
| | Schizophrenia | 7 | 2023 | 446 | 0.570 |
Why?
| | Drug Users | 2 | 2016 | 42 | 0.550 |
Why?
| | Gray Matter | 2 | 2015 | 91 | 0.530 |
Why?
| | Humans | 85 | 2026 | 144759 | 0.520 |
Why?
| | Male | 64 | 2025 | 72315 | 0.510 |
Why?
| | Tobacco Use Disorder | 1 | 2019 | 218 | 0.510 |
Why?
| | Adult | 47 | 2025 | 40449 | 0.510 |
Why?
| | Levodopa | 1 | 2017 | 41 | 0.510 |
Why?
| | Antiparkinson Agents | 1 | 2017 | 41 | 0.510 |
Why?
| | Sensation Disorders | 1 | 2017 | 41 | 0.500 |
Why?
| | Female | 63 | 2025 | 78271 | 0.490 |
Why?
| | Sexism | 1 | 2017 | 70 | 0.480 |
Why?
| | Neuropsychological Tests | 9 | 2016 | 1134 | 0.470 |
Why?
| | Ventral Striatum | 1 | 2015 | 10 | 0.440 |
Why?
| | Functional Laterality | 3 | 2013 | 241 | 0.440 |
Why?
| | Ethanol | 1 | 2019 | 627 | 0.430 |
Why?
| | Attention | 4 | 2005 | 457 | 0.410 |
Why?
| | Gyrus Cinguli | 5 | 2012 | 96 | 0.390 |
Why?
| | Cytokines | 1 | 2021 | 2061 | 0.390 |
Why?
| | Magnetic Resonance Angiography | 2 | 2009 | 251 | 0.380 |
Why?
| | Conduct Disorder | 4 | 2017 | 160 | 0.380 |
Why?
| | Patient Selection | 1 | 2017 | 719 | 0.380 |
Why?
| | Cognition | 2 | 2019 | 1266 | 0.370 |
Why?
| | Amphetamine-Related Disorders | 3 | 2025 | 48 | 0.370 |
Why?
| | Deep Brain Stimulation | 2 | 2025 | 212 | 0.360 |
Why?
| | Hippocampus | 7 | 2015 | 965 | 0.360 |
Why?
| | Healthcare Disparities | 1 | 2017 | 727 | 0.310 |
Why?
| | Inflammation | 1 | 2021 | 2878 | 0.300 |
Why?
| | Veins | 1 | 2009 | 68 | 0.290 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 4 | 2015 | 232 | 0.290 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2008 | 16 | 0.290 |
Why?
| | Spinal Cord Diseases | 1 | 2008 | 41 | 0.280 |
Why?
| | Atrophy | 6 | 2024 | 201 | 0.280 |
Why?
| | Middle Aged | 21 | 2025 | 35875 | 0.270 |
Why?
| | Executive Function | 1 | 2013 | 461 | 0.270 |
Why?
| | Reaction Time | 3 | 2013 | 438 | 0.270 |
Why?
| | Cues | 4 | 2019 | 326 | 0.260 |
Why?
| | Analysis of Variance | 4 | 2013 | 1306 | 0.260 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.240 |
Why?
| | Dementia, Vascular | 3 | 2000 | 21 | 0.230 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2020 | 154 | 0.230 |
Why?
| | Intralaminar Thalamic Nuclei | 1 | 2025 | 21 | 0.220 |
Why?
| | Neuroradiography | 1 | 2024 | 5 | 0.220 |
Why?
| | Evoked Potentials | 1 | 2005 | 128 | 0.210 |
Why?
| | Pilot Projects | 2 | 2021 | 1886 | 0.210 |
Why?
| | Methamphetamine | 1 | 2025 | 70 | 0.210 |
Why?
| | Amyloid | 1 | 2025 | 92 | 0.210 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2003 | 21 | 0.200 |
Why?
| | Delay Discounting | 1 | 2023 | 29 | 0.200 |
Why?
| | Drug Resistant Epilepsy | 1 | 2025 | 124 | 0.200 |
Why?
| | Comprehension | 1 | 2025 | 180 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 153 | 0.200 |
Why?
| | Reference Values | 6 | 2021 | 797 | 0.200 |
Why?
| | Interview, Psychological | 2 | 2013 | 94 | 0.190 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 2002 | 2 | 0.190 |
Why?
| | Central Nervous System Stimulants | 1 | 2025 | 185 | 0.190 |
Why?
| | Case-Control Studies | 5 | 2016 | 3604 | 0.190 |
Why?
| | Herpesvirus 1, Human | 1 | 2003 | 84 | 0.190 |
Why?
| | Young Adult | 8 | 2025 | 14105 | 0.190 |
Why?
| | Adolescent Development | 2 | 2021 | 72 | 0.190 |
Why?
| | Perioperative Care | 1 | 2025 | 231 | 0.180 |
Why?
| | Thoracic Vertebrae | 1 | 2002 | 79 | 0.180 |
Why?
| | Marijuana Abuse | 1 | 2025 | 211 | 0.180 |
Why?
| | Multimodal Imaging | 2 | 2019 | 124 | 0.170 |
Why?
| | Administration, Oral | 2 | 2019 | 847 | 0.170 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 13 | 0.170 |
Why?
| | Feedback, Psychological | 2 | 2013 | 23 | 0.170 |
Why?
| | Marijuana Use | 1 | 2025 | 213 | 0.170 |
Why?
| | Dementia | 1 | 2024 | 303 | 0.160 |
Why?
| | Photic Stimulation | 8 | 2017 | 264 | 0.160 |
Why?
| | Random Allocation | 1 | 2021 | 363 | 0.160 |
Why?
| | Benzylidene Compounds | 2 | 2010 | 20 | 0.160 |
Why?
| | Fingers | 2 | 2013 | 107 | 0.150 |
Why?
| | Immunotherapy | 1 | 2025 | 653 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2024 | 365 | 0.150 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3409 | 0.150 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2015 | 541 | 0.150 |
Why?
| | Oxygen | 4 | 2017 | 995 | 0.150 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2019 | 16 | 0.150 |
Why?
| | Cocaine-Related Disorders | 2 | 2012 | 132 | 0.150 |
Why?
| | Aged | 13 | 2024 | 25913 | 0.150 |
Why?
| | Cerebellum | 3 | 2013 | 223 | 0.150 |
Why?
| | Epilepsy | 1 | 2024 | 376 | 0.150 |
Why?
| | Tremor | 2 | 2017 | 98 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2019 | 170 | 0.140 |
Why?
| | Aged, 80 and over | 6 | 2024 | 8265 | 0.140 |
Why?
| | Smoking | 3 | 2012 | 1472 | 0.140 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 1998 | 99 | 0.130 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 323 | 0.130 |
Why?
| | Selection Bias | 1 | 2017 | 38 | 0.130 |
Why?
| | Cross-Over Studies | 4 | 2013 | 601 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1560 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2026 | 11679 | 0.120 |
Why?
| | Artifacts | 3 | 2009 | 139 | 0.120 |
Why?
| | Spinal Cord | 1 | 1998 | 380 | 0.120 |
Why?
| | DiGeorge Syndrome | 1 | 2016 | 34 | 0.120 |
Why?
| | Pyridines | 2 | 2010 | 605 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 6048 | 0.110 |
Why?
| | Organ Size | 3 | 2015 | 463 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 2 | 2009 | 583 | 0.110 |
Why?
| | Evoked Potentials, Visual | 3 | 2002 | 42 | 0.110 |
Why?
| | Mental Disorders | 1 | 2023 | 1168 | 0.110 |
Why?
| | Photoreceptor Cells | 2 | 1985 | 18 | 0.110 |
Why?
| | Brain Neoplasms | 1 | 2024 | 1318 | 0.110 |
Why?
| | Postural Balance | 1 | 2017 | 240 | 0.100 |
Why?
| | Problem Behavior | 1 | 2015 | 102 | 0.100 |
Why?
| | Nucleus Accumbens | 1 | 2015 | 132 | 0.100 |
Why?
| | Single-Blind Method | 2 | 2012 | 312 | 0.100 |
Why?
| | Brain Ischemia | 4 | 2000 | 358 | 0.100 |
Why?
| | Age Factors | 1 | 2021 | 3333 | 0.100 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2013 | 40 | 0.100 |
Why?
| | Adolescent | 11 | 2025 | 22428 | 0.100 |
Why?
| | Longitudinal Studies | 2 | 2021 | 2947 | 0.100 |
Why?
| | Personality Inventory | 1 | 2013 | 134 | 0.090 |
Why?
| | Heroin Dependence | 1 | 2012 | 33 | 0.090 |
Why?
| | Principal Component Analysis | 1 | 2013 | 197 | 0.090 |
Why?
| | Alcohol Drinking | 1 | 2019 | 826 | 0.090 |
Why?
| | Efficiency | 1 | 2012 | 103 | 0.090 |
Why?
| | Adolescent Behavior | 1 | 2017 | 501 | 0.090 |
Why?
| | Cognition Disorders | 2 | 2010 | 538 | 0.090 |
Why?
| | Emotions | 1 | 2017 | 578 | 0.090 |
Why?
| | Appetite Regulation | 1 | 2011 | 31 | 0.090 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.090 |
Why?
| | Fatal Outcome | 2 | 2019 | 307 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2026 | 17066 | 0.080 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 83 | 0.080 |
Why?
| | Research Design | 1 | 2017 | 1135 | 0.080 |
Why?
| | Regression Analysis | 1 | 2013 | 1003 | 0.080 |
Why?
| | Cerebrospinal Fluid | 2 | 2003 | 88 | 0.080 |
Why?
| | Comorbidity | 1 | 2015 | 1658 | 0.080 |
Why?
| | Inpatients | 1 | 2014 | 545 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1326 | 0.070 |
Why?
| | Sex Factors | 1 | 2015 | 2112 | 0.070 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2008 | 8 | 0.070 |
Why?
| | Temperance | 1 | 2008 | 20 | 0.070 |
Why?
| | Visual Perception | 1 | 2011 | 183 | 0.070 |
Why?
| | Nutritional Status | 1 | 2011 | 354 | 0.070 |
Why?
| | Disease Progression | 2 | 2008 | 2847 | 0.070 |
Why?
| | Energy Intake | 1 | 2011 | 499 | 0.070 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 321 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2000 | 630 | 0.070 |
Why?
| | Wechsler Scales | 1 | 2007 | 59 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 3 | 2024 | 2730 | 0.070 |
Why?
| | Chewing Gum | 1 | 2007 | 8 | 0.070 |
Why?
| | Alcohols | 1 | 2007 | 28 | 0.070 |
Why?
| | Exploratory Behavior | 1 | 2007 | 86 | 0.060 |
Why?
| | Eye Movements | 2 | 2010 | 92 | 0.060 |
Why?
| | Alcohol-Related Disorders | 1 | 2008 | 120 | 0.060 |
Why?
| | Event-Related Potentials, P300 | 2 | 2004 | 15 | 0.060 |
Why?
| | Parietal Lobe | 2 | 2005 | 60 | 0.060 |
Why?
| | Normal Distribution | 1 | 2006 | 22 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2003 | 1489 | 0.060 |
Why?
| | Rod Cell Outer Segment | 1 | 1985 | 4 | 0.060 |
Why?
| | Electroencephalography | 3 | 2003 | 532 | 0.060 |
Why?
| | Color Vision Defects | 1 | 1985 | 8 | 0.060 |
Why?
| | Models, Neurological | 1 | 2007 | 254 | 0.060 |
Why?
| | Dissociative Disorders | 1 | 2005 | 30 | 0.060 |
Why?
| | Spinal Nerve Roots | 1 | 2005 | 29 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2005 | 43 | 0.060 |
Why?
| | Taste | 1 | 2007 | 239 | 0.050 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2025 | 29 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2009 | 2029 | 0.050 |
Why?
| | Endothelium, Vascular | 1 | 2011 | 965 | 0.050 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2005 | 133 | 0.050 |
Why?
| | Aspartic Acid | 3 | 2000 | 88 | 0.050 |
Why?
| | Surgery, Computer-Assisted | 1 | 2025 | 84 | 0.050 |
Why?
| | Aphasia | 1 | 2003 | 24 | 0.050 |
Why?
| | Connectome | 1 | 2025 | 95 | 0.050 |
Why?
| | Ocular Motility Disorders | 1 | 2004 | 41 | 0.050 |
Why?
| | Psychopathology | 1 | 2023 | 56 | 0.050 |
Why?
| | Child | 5 | 2024 | 22633 | 0.050 |
Why?
| | Brain Diseases | 1 | 2024 | 152 | 0.050 |
Why?
| | Personnel Selection | 1 | 2024 | 93 | 0.050 |
Why?
| | Temporal Lobe | 1 | 2003 | 104 | 0.050 |
Why?
| | Pattern Recognition, Visual | 1 | 2004 | 105 | 0.050 |
Why?
| | Echo-Planar Imaging | 1 | 2002 | 23 | 0.050 |
Why?
| | Heart Rate | 1 | 2007 | 855 | 0.050 |
Why?
| | Acetazolamide | 1 | 2022 | 26 | 0.050 |
Why?
| | United States | 3 | 2025 | 15966 | 0.050 |
Why?
| | Mental Processes | 1 | 2002 | 38 | 0.050 |
Why?
| | Fourier Analysis | 1 | 2002 | 41 | 0.050 |
Why?
| | Nerve Fibers, Myelinated | 2 | 2005 | 47 | 0.050 |
Why?
| | Radiology | 1 | 2024 | 174 | 0.050 |
Why?
| | Decompression, Surgical | 1 | 2002 | 116 | 0.040 |
Why?
| | Motor Activity | 1 | 2006 | 721 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2024 | 547 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2024 | 302 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2004 | 271 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2025 | 704 | 0.040 |
Why?
| | Stroke | 2 | 2019 | 1256 | 0.040 |
Why?
| | Language | 1 | 2024 | 321 | 0.040 |
Why?
| | Incidental Findings | 1 | 2021 | 80 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2003 | 1054 | 0.040 |
Why?
| | Liver Diseases | 1 | 2003 | 304 | 0.040 |
Why?
| | Blood Pressure | 1 | 2007 | 1769 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 887 | 0.040 |
Why?
| | Seizures | 1 | 2003 | 460 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1985 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 2005 | 484 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2019 | 38 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2019 | 42 | 0.040 |
Why?
| | Cerebral Infarction | 1 | 1999 | 47 | 0.040 |
Why?
| | Coloring Agents | 1 | 2019 | 93 | 0.040 |
Why?
| | Algorithms | 1 | 2007 | 1837 | 0.040 |
Why?
| | Optical Imaging | 1 | 2019 | 64 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 985 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2019 | 151 | 0.040 |
Why?
| | Brain Chemistry | 1 | 1998 | 116 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 413 | 0.030 |
Why?
| | Cannabis | 1 | 2025 | 509 | 0.030 |
Why?
| | Obesity | 1 | 2011 | 3077 | 0.030 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 598 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 271 | 0.030 |
Why?
| | Animals | 2 | 2019 | 38058 | 0.030 |
Why?
| | Cerebral Ventricles | 1 | 1997 | 54 | 0.030 |
Why?
| | Motor Neurons | 1 | 1998 | 234 | 0.030 |
Why?
| | Visual Acuity | 1 | 2019 | 489 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 891 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 2027 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 851 | 0.030 |
Why?
| | Empathy | 1 | 2017 | 182 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 45 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 551 | 0.030 |
Why?
| | Glucose | 1 | 1999 | 1047 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 7173 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5868 | 0.020 |
Why?
| | Hyperphagia | 1 | 2011 | 38 | 0.020 |
Why?
| | Sensation | 1 | 2011 | 55 | 0.020 |
Why?
| | Labor, Induced | 1 | 2011 | 39 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 97 | 0.020 |
Why?
| | Thinness | 1 | 2011 | 99 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2011 | 266 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5960 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 126 | 0.020 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 1 | 2010 | 93 | 0.020 |
Why?
| | Food | 1 | 2011 | 149 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 209 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7990 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 277 | 0.020 |
Why?
| | Creatine | 2 | 2000 | 63 | 0.020 |
Why?
| | Hemodynamics | 1 | 2013 | 1121 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1047 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 478 | 0.020 |
Why?
| | Dominance, Cerebral | 1 | 2007 | 56 | 0.020 |
Why?
| | Aspirin | 1 | 2011 | 399 | 0.020 |
Why?
| | Nerve Fibers | 1 | 2007 | 104 | 0.020 |
Why?
| | Cranial Nerves | 1 | 2005 | 12 | 0.010 |
Why?
| | Sural Nerve | 1 | 2005 | 21 | 0.010 |
Why?
| | Genotype | 1 | 2010 | 1833 | 0.010 |
Why?
| | Weight Loss | 1 | 2011 | 836 | 0.010 |
Why?
| | Graves Disease | 1 | 2005 | 30 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 127 | 0.010 |
Why?
| | Visual Pathways | 1 | 2005 | 61 | 0.010 |
Why?
| | Schizophrenic Psychology | 1 | 2005 | 97 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2005 | 273 | 0.010 |
Why?
| | Area Under Curve | 1 | 2005 | 330 | 0.010 |
Why?
| | Treatment Failure | 1 | 2005 | 365 | 0.010 |
Why?
| | Genetic Markers | 1 | 2005 | 331 | 0.010 |
Why?
| | Early Diagnosis | 1 | 2005 | 249 | 0.010 |
Why?
| | Gene Frequency | 1 | 2005 | 481 | 0.010 |
Why?
| | Axons | 1 | 2005 | 201 | 0.010 |
Why?
| | Visual Fields | 1 | 2004 | 115 | 0.010 |
Why?
| | Myelin Sheath | 1 | 2005 | 168 | 0.010 |
Why?
| | Phenytoin | 1 | 1983 | 21 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2145 | 0.010 |
Why?
| | Electrolytes | 1 | 1983 | 55 | 0.010 |
Why?
| | Neural Inhibition | 1 | 2004 | 178 | 0.010 |
Why?
| | Head | 1 | 2004 | 120 | 0.010 |
Why?
| | Visual Cortex | 1 | 2002 | 84 | 0.010 |
Why?
| | Movement | 1 | 2004 | 293 | 0.010 |
Why?
| | Risk | 1 | 2004 | 911 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 846 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 1999 | 71 | 0.010 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 103 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 7190 | 0.010 |
Why?
| | Protons | 1 | 1997 | 95 | 0.010 |
Why?
| | Choline | 1 | 1998 | 136 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2004 | 2363 | 0.010 |
Why?
| | Biomarkers | 1 | 2005 | 4271 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2925 | 0.010 |
Why?
| | Dogs | 1 | 1983 | 437 | 0.000 |
Why?
|
|
Tanabe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|